Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients

Internal Medicine

Volumn 47, Issue 15, 2008, Pages 1379-1386

  Okano, Kazuhiro ^a,b   Ohba, Takashi ^b   Matsugami, Keiko ^b   Uchida, Keiko ^a   Nitta, Kosaku ^a   Kabaya, Takashi ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Minami Senju Hospital   (Japan)

Author keywords

Adiponectin; Hemodialysis; Leptin; TNF

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; IRON; LEPTIN; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG TARGETING; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; JAPANESE; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT CARE; PROGNOSIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADIPOKINES; ADIPONECTIN; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53749087041     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1145     Document Type: Article

References (30)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 2486-2497, 2001.
2. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the national Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27: 1182-1186, 2004.
3. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome -a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Med 23: 469-480, 2006.
4. Kitiyakara C, Yamwong S, Cheepudomwit S, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 71: 693-700, 2007.
5. Committee on Evaluation of Diagnostic Standards for Metabolic. Syndrome (CEDSMS). Definition and diagnostic standards for metabolic syndrome. Nippon Naika Gakkai Zasshi 94: 794-809, 2005 (in Japanese, Abstract in English).
6. The Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for Study of Obesity (JSSO). New criteria for 'Obesity disease' in Japan. Circ J 66: 987-992, 2002.
7. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 15: 2775-2791, 2004.
8. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16: 1091-1098, 2005.
9. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451-459, 2004.
10. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 83: 202-210, 2006.
11. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity-related diseases. Horm Res 60 (Suppl 3): 56-59, 2003.
12. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptor. Endocr Rev 26: 439-451, 2005.
13. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Neprol 13: 134-141, 2002.
14. Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum. Kidney Int 71: 1195-1197, 2007.
15. Pecoits-Filho R, Lindholm B, Stenvinkel P, et al. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -the heart of the matter. Nephrol Dial Transplant 17(Suppl 11): 28-31, 2002.
16. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26: 2493-2499, 2003.
17. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737, 2002.
18. Masuzaki H, Ogawa Y, Aizawa-Abe M, et al. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 48: 1615-1622, 1999.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
20. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
21. Hosoda K, Masuzaki H, Ogawa Y, et al. Development of radioimmunoassay for human leptin. Biochem Biophys Res Commun 221: 234-239, 1996.
22. Stejskal D, Ruzicka V, Adamovska S, et al. Adiponectin concentrations as a criterion of metabolic control in persons with type 2 diabetes mellitus? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147: 167-172, 2003.
23. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 22: 171-178, 2007.
24. Kim MJ, Yoo KH, Park HS, et al. Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus. Yonsei Med J 46: 42-50, 2005.
25. Ohashi N, Kato A, Misaki T, et al. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 47: 485-491, 2008.
26. Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 51: 1980-1985, 1997.
27. Nordfors L, Lonnqvist F, Heimburger O, et al. Lowleptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54: 1267-1275, 1998.
28. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogeniclipoproteins in end-stage renal disease. Am J Kidney Dis 38: S30-S33, 2001.
29. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010, 2001.
30. Mallamaci F, Tripepi G, Zoccali C. Leptin in end stage renal disease (ESRD): a link between fat mass, bone and the cardiovascular system. J Nephrol 18: 464-468, 2005.